

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 January 2004 (29.01.2004)

PCT

(10) International Publication Number  
**WO 2004/009593 A1**

- (51) International Patent Classification<sup>7</sup>: **C07D 471/04**, A61K 31/47, A61P 31/12 // (C07D 471/04, 235:00, 221:00)
- (21) International Application Number: PCT/US2003/023153
- (22) International Filing Date: 23 July 2003 (23.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/397,607 23 July 2002 (23.07.2002) US
- (71) Applicant (for all designated States except BB, US): **TEVA PHARMACEUTICAL INDUSTRIES LTD.** [IL/IL]; 5 Basel Street, P.O. Box 3190, Petah Tiqva, 49131 (IL).
- (71) Applicant (for BB only): **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Horsham Road, P.O. Box 1090, North Wales, PA 19454-1090 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **VALERIANO, Merli** [IT/IT]; Via Cesare Battisti N 21, 23894 Cremella Lecco, IT (IT). **DAVERIO, Paola** [IT/IT]; Piazza Giovanni XXIII N1, 20058 Villasanta, Milano (IT). **BIANCHI, Stefano** [IT/IT]; Via Ronchetto N 20, 22100 Breccia Como, 22100 (IT).
- (74) Agent: **BRAINARD, Charles, R.**; Kenyon & Kenyon, One Broadway, New York, NY 10004-1050 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PREPARATION OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES VIA 1H-IMIDAZO [4,5-C]QUINOLIN-4-PHTHALIMIDE INTERMEDIATES

(57) Abstract: The invention provides 1H-imidazo(4,5-C)quinolin-4-phthalimide intermediates useful in the synthesis of 1H-imidazo(4,5-C)quinoline-4-amines, particularly Imiquimod. The invention further provides a method for making the intermediates and a method for making 1H-imidazo(4,5-C)quinoline-4-amines via the intermediates.



WO 2004/009593 A1

## PREPARATION OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES VIA 1H-IMIDAZO[4,5-C]QUINOLIN-4-PHTHALIMIDE INTERMEDIATES

**CROSS-REFERENCE TO RELATED APPLICATION**


5           This application claims the benefit of provisional application Serial No. 60/397,607, filed July 23, 2002, the contents of which is incorporated herein.

**FIELD OF THE INVENTION**

10           The present invention relates to a process for the synthesis of 1H-imidazo[4,5-c]quinoline 4-phthalimide intermediates useful in preparing 1H-imidazo [4,5-C] quinoline 4-amines, a process for preparing 1H-imidazo [4,5-C] quinoline 4-amines using such intermediates; and, to the 1H-imidazo[4,5-c] quinoline 4-phthalimide intermediates. More particularly, the present invention relates to a novel process for the preparation of 1-isobutyl-1H-imidazo [4,5-C] quinoline 4-amine (Imiquimod) by introducing an amino group in the 4 position of 1-isobutyl-1H-  
15 imidazo [4,5-C] quinolin-4-amine via a 1-isobutyl-1H-imidazo[4,5-c] quinoline 4-phthalimide intermediate, and to the 1-isobutyl- 1H-imidazo[4,5-c] quinoline 4-phthalimide intermediate.

**BACKGROUND OF THE INVENTION**

20           Imiquimod, 1-isobutyl-1H-imidazo [4,5-C] quinolin-4-amine, is an immune response modifier, useful for treating viral infections, such as genital warts. Imiquimod is disclosed in U.S. patents 4,689,338 and 5,238,944 and has the structure:



Several methods are known in the art for making 1H-imidazo [4,5-c]quinoline 4-amines, including Imiquimod. The amino group in the 4 position has been introduced in essentially three

ways: The first is by nucleophilic substitution of a leaving group, *e.g.*, Cl, triflate, etc., with ammonia, dibenzylamine or an azido group; the second is by reacting 1-isobutyl-1H-imidazo [4,5-c] quinoline-N-oxide with ammonium hydroxide or ammonium salts in the presence of tosyl chloride at 0-5 °C; and the third is by reacting 1-isobutyl-1H-imidazo[4,5-c]quinoline-N-oxide with benzoyl isocyanate.

Nucleophilic substitution reactions are disclosed in, for example, WO 97/48704, WO 92/06093, U.S. patents 5,395,937, 5,756,747, 4,988,815, 5,602,256, 5,578,727, 4,698,348, 4,689,388, European patents EP 145340, EP 0385630, EP 310950 and JP 04193866.

Specifically, in WO 97/48704 the amino group is introduced by reaction of a 4-chloro derivative with sodium azide to obtain a tetrazole moiety. Reaction of the tetrazole moiety with triphenylphosphine gives the 4-amino derivative. In U.S. patent 5,395,937, a 4-triflate derivative is reacted with dibenzylamine. The catalytic reduction of the 4-dibenzylamino derivative places an amino group in the 4-position. U.S. patent 5,756,474, discloses a nucleophilic substitution with ammonia on a 4-chloro derivative, obtained by isomerization of 1-isobutyl-1H-imidazo[4,5-c]quinoline-N-oxide to the 4-hydroxy derivative, followed by reaction with POCl<sub>3</sub>. The following patents all disclose a nucleophilic substitution of 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-chloro with ammonia at high temperature and pressure: 4,988,815, 5,602,256, 5,578,727, 4,698,348, 4,689,388, EP 145340, JP 04193866, EP 0385630, and EP 310950.

WO 92/06093 discloses reacting 1-isobutyl-1H-imidazo [4,5-c] quinoline-N-oxide with ammonium hydroxide or ammonium salts in the presence of tosyl chloride at 0-5 °C.


WO 92/15581 discloses reacting 1-isobutyl-1H-imidazo[4,5-c]quinoline-N-oxide with benzoyl isocyanate.

However, a need exists in the art for making 1H-imidazo [4,5-C] quinoline 4-amines, especially Imiquimod, in high purity and high yield and which does not require high temperature or pressure.

**SUMMARY OF THE INVENTION**

In one aspect, the present invention is directed to a compound of formula

(II):



wherein

R<sub>1</sub> is selected from the group consisting of: hydrogen; a straight or branched chain alkyl of one to about 10 carbon atoms, optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; straight or branched chain alkenyl of 2 to about 10 carbon atoms, wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen, and wherein the straight or branched chain alkyl is optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; hydroxyalkyl of one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;

10

15

20

R<sub>2</sub> is selected from the group consisting of: hydrogen; straight or branched chain alkyl containing one to about eight carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower

25


alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;

R is independently selected from the group consisting of: alkoxy of one to about four carbon atoms; alkyl of one to about four carbon atoms; and halogen; and


5 n is an integer from 0 to 2, with the proviso that if n is 2, then said groups together contain no more than 6 carbon atoms.

In a preferred embodiment, R<sub>1</sub> is isobutyl, R<sub>2</sub> is hydrogen, n is 0.

In another aspect, the present invention is directed to a process for preparing a 1H-imidazo[4,5-c]quinoline 4-phthalimide of formula (II) comprising reacting a compound of  
10 formula (III) with phthalimide in a suitable organic solvent, wherein R, R<sub>1</sub>, R<sub>2</sub> and n are defined above.



In another aspect, the present invention is directed to a process for preparing a compound of formula (I):



15 comprising reacting a compound of formula (II) with hydrazine hydrate in a suitable solvent, wherein R, R<sub>1</sub>, R<sub>2</sub> and n are defined above.

These and other aspects of the present invention will now be described in more detail

with reference to the following detailed description of the invention.

### DETAILED DESCRIPTION OF THE INVENTION

In one aspect, the present invention is directed to a process for preparing 1H-imidazo[4,5-c]quinoline-4-amines of formula (I). The preferred 1H-imidazo[4,5-c]quinoline-4-amine is Imiquimod. However, the inventive process can be used to prepare any compound within the scope of formula (I), including those disclosed in U.S. patents 5,756,747, 5,395,937, 4,689,338, EP 385630, WO 97/48704, WO 92/06093 and WO 92/15581, all of which are incorporated by reference in their entirety herein.


The invention is also directed to novel 1H-imidazo[4,5-c] quinoline 4-phthalimide intermediates of formula (II), which are useful in preparing 1H-imidazo[4,5-c]quinoline-4-amines of formula (I), and to a process for preparing the intermediates of formula (II).

The 1H-imidazo[4,5-c] quinoline 4-phthalimide intermediates of formula (II) are prepared by reacting a 1H-imidazo[4,5-c] quinoline N-oxide of formula (III) with phthalimide. The reaction is carried out in a solvent and a base. Preferred solvents include methylene chloride and ethylacetate. Preferred bases include tri-n-butylamine, triethylamine and triisobutylamine. The most preferred mixture is ethylacetate and tri-n-butylamine. The reaction is preferably carried out in the presence of benzoyl chloride. The reaction is preferably carried out at a temperature of between about 0-10 °C, over a period of about one hour.

The 1H-imidazo[4,5-c] quinoline N-oxides of formula (III) can be obtained by any method known in the art, including those disclosed in: U.S. patent 5,756,747, WO 92/06093 and WO 92/15581, all of which are incorporated by reference in their entirety herein.

The 1H-imidazo[4,5-c] quinoline 4-phthalimide intermediates of formula (II) are then reacted with hydrazine hydrate in a suitable solvent to form 1H-imidazo[4,5-c]quinoline-4-amines of formula (I). Water is a preferred solvent. Preferably, isoctyl alcohol is added to avoid foam formation. The reaction is preferably carried out at a temperature of between about 94-95 °C, over a period of about 4-5 hours.

One reaction scheme that may be used to make 1H-imidazo[4,5-c]quinoline-4-amines of formula (I) is shown below:



The present invention is illustrated in further detail with reference to the following non-limiting examples.

#### Example 1

##### Preparation of 4-isobutyl-3-nitro quinoline

5 4-chloro-3-nitro-quinoline is reacted with isobutyl amine in the presence of triethylamine (TEA) at between -10 and +15 °C in toluene, while excluding moisture. After washing and phase separation, the organic solution is ready for the next step.

#### Example 2

##### Preparation of 4-isobutyl-3-amino quinoline

10 The nitro group on the 4-isobutyl-3-nitro quinoline produced in Example 1 is reduced by catalytic reduction using toluene as solvent, Pd/C 5% (50% wet) as catalyst, at 40-45 °C and atmospheric pressure to produce 4-isobutyl 3-amino quinoline. The rate of reaction depends on efficiency of stirring. After catalyst filtration the solution is ready for the next step.

#### Example 3

##### Preparation of 1-isobutyl-1H-imidazo[4,5-c]quinoline

15 The cyclization of 4-isobutyl 3-amino quinoline produced in Example 2 is carried out in toluene at 102-110 °C using TEOF (triethyl orthoformate) and 20% moles of formic acid to increase the rate of reaction, to produce 1-isobutyl-1H-imidazo[4,5-c]quinoline. Before addition of TEOF, in order to prevent its hydrolysis, it is necessary to remove water formed during the  
20 catalytic reduction by azeotropic distillation. A mixture of ethanol and toluene is distilled during the reaction to maintain the internal temperature at 102-110 °C.

#### Example 4

##### Preparation of 1-isobutyl-1H-imidazo[4,5-c]quinoline N-oxide

25 The oxidation of 1-isobutyl-1H-imidazo[4,5-c]quinoline produced in Example 3 is carried out in toluene at 40-45 °C using peracetic acid as oxidant to produce 1-isobutyl-1H-imidazo[4,5-c]quinoline N-oxide. The product is isolated by filtration after addition of a sodium sulfate solution and ammonium hydroxide.



### Example 5

#### Preparation of 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-phthalimide

93 ml of methylene chloride and 15 g of 1-isobutyl-1H-imidazo[4,5-c]quinoline N-oxide (HPLC= 95%) are loaded into a 250 ml three necked round flask. Then 24.55 g of tri n-  
5 butylamine (98%) and 10.06 g of phthalimide (99%) are added to the flask under nitrogen and stirring. The suspension formed is cooled to 0 °C and the following solution is dropped into the suspension over 1 hour: 12.7 g of benzoyl chloride (98%) in 13 ml of methylene chloride, as the temperature is kept between 0-10 °C. The mixture is stirred at room temperature for about 30 minutes and a sample is taken. HPLC analysis shows that there is 0.32% of the starting material,  
10 87.72% of the target product, and 0.43% of the 4-hydroxy derivative. The solution is filtered and the filter cake is washed 3 times with 10 ml of methylene chloride. The wet filter cake is resuspended at 25 °C for at least 7 hours in 100 ml of methanol. After resuspension the solution is filtered and the filter cake is washed 2 times with 10 ml of methanol. Prior to the second filtration, HPLC shows that there is  $\leq 0.4\%$  of the starting material and  $\leq 0.05\%$  of the 4-  
15 hydroxy derivative. The solid is dried under vacuum at 50 °C for 15 hours. The dry solid weighs 18 g. HPLC analysis shows that the solid is 98.98% pure and the yield is 81.52% based on the starting material (1-isobutyl-1H-imidazo[4,5-c]quinoline N-oxide).

### Example 6

#### Preparation of 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine

20 72 ml water and 18 g 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-phthalimide (HPLC=98.98%) are heated to 70 °C in a 250 ml reactor. 4.8 g hydrazine hydrate is dropped into the reactor while stirring and then 2 ml iso-octyl alcohol is added to the reactor. The reaction mixture is heated at 94-95 °C for 4 hours and a sample is taken. HPLC analysis shows that there is 6.16% starting material and 94 % target material. To obtain a complete conversion  
25 of starting material the reaction is allowed to proceed for another hour. The reaction mixture is cooled at 60°C and 180 ml of methanol is added. The mixture is warmed at reflux for 15 minutes, then cooled at room temperature. The solution is filtered and the cake is washed 3 times with 15 ml of a 3.5:1 mixture of methanol and water. The wet solid obtained weighs 22.4 g. HPLC analysis shows that its purity is 98.23% (no phthalhydrazide integration). The wet

solid is treated with 180 ml of water and 5.2 g of 37% HCl at 90-93 °C for 30 minutes. The hot suspension is filtered and the cake is washed 3 times with 15 ml of water. The solid is phthalhydrazide weighing 4.5 g. The hot solution is treated at 90-93 °C with 0.115 g Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> and 0.576 g charcoal. After 30 minutes the charcoal is filtered off and the cake is washed two times with 10 ml water. The solution is cooled at 70-75 °C and 10 g of 30% NaOH is added to pH 11.54, at which time a solid precipitates. The mixture is cooled to room temperature and after 1 hour the solid is filtered and the cake is washed 3 times with 10 ml water. 15.1 g of crude wet Imiquimod (pale pink color) is obtained. The Imiquimod is dried to a weight of 10.57 g. HPLC shows the purity to be 98.12%. There is 1.55% phthalhydrazide present.

10

### Example 7

#### Purification of 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine


53.55 ml water, 23.62 ml butyl alcohol, 10.57 crude Imiquimod and 4.77 g of 37% HCl are loaded into a 100 ml reactor. The mixture is heated to 55-60 °C to obtain a solution. The solution is cooled to room temperature and a white crystal precipitates. The solid is filtered and washed 2 times with 5 ml butyl alcohol. 13.63 g of wet Imiquimod chloridate is obtained. HPLC analysis shows that there is 99.89% Imiquimod and 0.01% phthalhydrazide. 120 ml water and 13.63 g of wet Imiquimod chloridate are loaded into a 250 ml reactor and heated to 85-90 °C. The hot solution is filtered and the cake is washed with 5 ml of hot water. Then 0.024 g of Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> is added. The colorless solution is cooled to 70-75 °C and 5.3 g of 30% NaOH is added to provide a pH of 9.7, at which point a solid precipitates. The suspension is cooled to 20 °C and filtered. The cake is washed 3 times with 5 ml water and twice with 5 ml methanol. During the washes no chloride was detected by silver nitrate. The solid is dried under vacuum at 50 °C for 8 hours. 8.98 g of Imiquimod (off-white color) is obtained. HPLC shows the purity to be 99.94% and the yield to be 63.3% based on the starting material (1-isobutyl-1H-imidazo[4,5-c]quinoline N-oxide).

25

Having thus described the invention with reference to particular preferred embodiments and illustrated it with examples, those of skill in the art may appreciate modifications to the invention as described and illustrated that do not depart from the spirit and scope of the invention as disclosed in the specification.

What is claimed is:

1. A compound of formula (II):



wherein

5  $R_1$  is selected from the group consisting of: hydrogen; a straight or branched chain alkyl of one to about 10 carbon atoms, optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; straight or branched chain alkenyl of 2 to about 10 carbon atoms, wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen, and wherein the straight or branched chain alkyl is optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; hydroxyalkyl of one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;

20  $R_2$  is selected from the group consisting of: hydrogen; straight or branched chain alkyl containing one to about eight carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower

alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;


R is independently selected from the group consisting of: alkoxy of one to about four carbon atoms; alkyl of one to about four carbon atoms; and halogen; and

5 n is an integer from 0 to 2, with the proviso that if n is 2, then said groups together contain no more than 6 carbon atoms.


2. A compound of claim 1, wherein R<sub>1</sub> is isobutyl, R<sub>2</sub> is hydrogen, and n is 0.

3. A process for preparing a 1H-imidazo[4,5-c]quinoline 4-phthalimide of formula (II):

10



comprising reacting a compound of formula (III):



with phthalimide, wherein

R<sub>1</sub> is selected from the group consisting of: hydrogen; a straight or branched chain alkyl

of one to about 10 carbon atoms, optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; straight or branched chain alkenyl of 2 to about 10 carbon atoms, wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen, and wherein the straight or branched chain alkyl is optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; hydroxyalkyl of one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;

$R_2$  is selected from the group consisting of: hydrogen; straight or branched chain alkyl containing one to about eight carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;


R is independently selected from the group consisting of: alkoxy of one to about four carbon atoms; alkyl of one to about four carbon atoms; and halogen; and

n is an integer from 0 to 2, with the proviso that if n is 2, then said groups together contain no more than 6 carbon atoms.


4. The process of claim 3, wherein  $R_1$  is isobutyl,  $R_2$  is hydrogen, and n is 0.

5. The process of claim 3 or claim 4, wherein the reaction takes place in the presence of a base and a solvent

6. The process of claim 5, wherein the solvent is selected from the group consisting of methylene chloride and ethylacetate and the base is selected from the group consisting of tri-n-butylamine, triethylamine, and triisobutylamine.
7. The process of claim 6, wherein the solvent is ethylacetate and the base is tri-n-butylamine.
8. The process of claim 5, wherein the reaction further takes place in the presence of an organic acid halide.
9. The process of claim 8, wherein the organic acid halide is benzoyl chloride.
10. The process of claim 3 or claim 4, wherein the reaction takes place at a temperature of between about 0 to about 10 °C.
11. The process of claim 3 or claim 4, wherein a compound of formula (III) and phthalimide are reacted over a period of about 1 hour.
12. A process for preparing a compound of formula (I):



comprising reacting a compound of formula (II):



with hydrazine hydrate, wherein

$R_1$  is selected from the group consisting of: hydrogen; a straight or branched chain alkyl of one to about 10 carbon atoms, optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; straight or branched chain alkenyl of 2 to about 10 carbon atoms, wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen, and wherein the straight or branched chain alkyl is optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; hydroxyalkyl of one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;


$R_2$  is selected from the group consisting of: hydrogen; straight or branched chain alkyl containing one to about eight carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;

$R$  is independently selected from the group consisting of: alkoxy of one to about four

carbon atoms; alkyl of one to about four carbon atoms; and halogen; and

n is an integer from 0 to 2, with the proviso that if n is 2, then said groups together contain no more than 6 carbon atoms.


13. The process of claim 12, wherein R<sub>1</sub> is isobutyl, R<sub>2</sub> is hydrogen, and n is 0.
- 5 14. The process of claim 11 or claim 12, wherein the reaction takes place in the presence of a solvent and isooctyl alcohol.
15. The process of claim 14, wherein the solvent is water.
16. The process of claim 11 or claim 12, wherein the reaction is carried out at a temperature of between about 94-95 °C.
- 10 17. The process of claim 11 or claim 12, wherein the compound of formula II and hydrazine hydrate are reacted for a period of about 4 to about 5 hours.
18. A process for preparing a compound of formula (I):




comprising:

- 15 a) preparing a compound of formula (II):





by reacting a compound of formula (III):



with phthalimide; and

- 5           b) converting the compound of formula II to a compound of formula (I), wherein
- $R_1$  is selected from the group consisting of: hydrogen; a straight or branched chain alkyl of one to about 10 carbon atoms, optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; straight or branched chain alkenyl of 2 to about
- 10       10 carbon atoms, wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen, and wherein the straight or branched chain alkyl is optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; hydroxyalkyl of one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is
- 15       alkanoyloxy of two to about four carbon atoms or benzoyloxy and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties

independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;


$R_2$  is selected from the group consisting of: hydrogen; straight or branched chain alkyl containing one to about eight carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;

$R$  is independently selected from the group consisting of: alkoxy of one to about four carbon atoms; alkyl of one to about four carbon atoms; and halogen; and

$n$  is an integer from 0 to 2, with the proviso that if  $n$  is 2, then said groups together contain no more than 6 carbon atoms.


19. The process of claim 18, wherein  $R_1$  is isobutyl,  $R_2$  is hydrogen, and  $n$  is 0.

20. A process for preparing a compound of formula (I):



comprising:

a) preparing a compound of formula (II):



and

b) reacting the compound of formula (II) with hydrazine hydrate to form a compound of formula (I), wherein

5  $R_1$  is selected from the group consisting of: hydrogen; a straight or branched chain alkyl of one to about 10 carbon atoms, optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; straight or branched chain alkenyl of 2 to about 10 carbon atoms, wherein the olefinic unsaturation in the alkenyl group is at least one carbon atom removed from the 1-nitrogen, and wherein the straight or branched chain alkyl is optionally substituted with a substituent selected from the group consisting of lower alkyl, cycloalkyl of 3 to about 6 carbon atoms, wherein said cycloalkyl is optionally substituted with a lower alkyl group; hydroxyalkyl of one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain more than 6 carbon atoms;

20  $R_2$  is selected from the group consisting of: hydrogen; straight or branched chain alkyl containing one to about eight carbon atoms; benzyl; (phenyl)ethyl; and phenyl, wherein said benzyl, (phenyl)ethyl and phenyl substituents are optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, and halogen, with the proviso that when the benzene ring is substituted by two such

moieties, then the moieties together contain more than 6 carbon atoms;

R is independently selected from the group consisting of: alkoxy of one to about four carbon atoms; alkyl of one to about four carbon atoms; and halogen; and

n is an integer from 0 to 2, with the proviso that if n is 2, then said groups together  
5 contain no more than 6 carbon atoms.

21. The process of claim 20, wherein  $R_1$  is isobutyl,  $R_2$  is hydrogen, and n is 0.

22. A compound of claim 1, produced by the process of claim 3.

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D471/04 A61K31/47 A61P31/12 //(C07D471/04,235:00,  
221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 689 338 A (GERSTER JOHN F) 25 August 1987 (1987-08-25) cited in the application reaction scheme on page 3 and column 6, lines 27 to 36 the whole document	3,12,20
A	WO 92 06093 A (MINNESOTA MINING & MFG) 16 April 1992 (1992-04-16) cited in the application step (5) according to reaction scheme on page 4 the whole document	3,12,20
A	WO 92 15582 A (MINNESOTA MINING & MFG) 17 September 1992 (1992-09-17) page 12, line 12 - line 31 reaction scheme on page 14, step (11)	1,3,12, 20

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

24 November 2003

Date of mailing of the international search report

03/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Goss, I

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4689338	A	25-08-1987	CZ 9103904 A3 17-03-1993
			MX 9203474 A1 01-07-1992
			SK 390491 A3 12-09-2000
			AT 49763 T 15-02-1990
			AT 84525 T 15-01-1993
			AU 2991189 A 15-06-1989
			AU 581190 B2 16-02-1989
			AU 3540284 A 23-05-1985
			BR 1100396 A3 31-08-1999
			CA 1271477 A1 10-07-1990
			DE 3481124 D1 01-03-1990
			DE 3486043 D1 25-02-1993
			DE 3486043 T2 03-06-1993
			DK 135791 A 16-07-1991
			DK 135891 A ,B, 16-07-1991
			DK 135991 A ,B, 16-07-1991
			DK 136091 A ,B, 16-07-1991
			DK 136191 A ,B, 16-07-1991
			DK 542684 A ,B, 19-05-1985
			EP 0145340 A2 19-06-1985
			EP 0310950 A1 12-04-1989
			ES 8603477 A1 16-04-1986
			IE 57874 B1 05-05-1993
			IL 73534 A 23-12-1990
			IL 84537 A 23-12-1990
			JP 5086391 B 10-12-1993
			KR 9005557 B1 31-07-1990
			NO 844565 A ,B, 20-05-1985
			NO 890822 A ,B, 20-05-1985
			NO 890823 A ,B, 20-05-1985
			NO 890824 A ,B, 20-05-1985
			NO 890825 A ,B, 20-05-1985
			NO 890826 A ,B, 20-05-1985
NZ 210228 A 27-01-1989			
PH 22338 A 12-08-1988			
WO 9206093	A	16-04-1992	AT 121088 T 15-04-1995
			CA 2093132 A1 06-04-1992
			DE 69108920 D1 18-05-1995
			DE 69108920 T2 30-11-1995
			DK 553202 T3 03-07-1995
			EP 0553202 A1 04-08-1993
			ES 2071340 T3 16-06-1995
			HU 63416 A2 30-08-1993
			HU 217080 B 29-11-1999
			IE 913307 A1 08-04-1992
			NZ 239873 A 23-12-1993
			WO 9206093 A1 16-04-1992
			US 5367076 A 22-11-1994
WO 9215582	A	17-09-1992	AT 179711 T 15-05-1999
			AT 229943 T 15-01-2003
			AU 658621 B2 27-04-1995
			AU 1566992 A 06-10-1992
			AU 673309 B2 31-10-1996
			AU 2715795 A 21-09-1995
			CA 2104782 A1 02-09-1992
			CA 2289219 C 20-05-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9215582	A	CZ 9301788 A3	18-10-1995
		DE 69229114 D1	10-06-1999
		DE 69229114 T2	04-11-1999
		DE 69232878 D1	30-01-2003
		DE 69232878 T2	20-11-2003
		DK 582581 T3	08-11-1999
		DK 872478 T3	31-03-2003
		EP 0582581 A1	16-02-1994
		EP 0872478 A2	21-10-1998
		ES 2131070 T3	16-07-1999
		ES 2186034 T3	01-05-2003
		HU 67026 A2	30-01-1995
		HU 211242 B3	28-11-1995
		HU 220667 B1	29-04-2002
		HU 222247 B1	28-05-2003
		HU 222251 B1	28-05-2003
		HU 222250 B1	28-05-2003
		IE 920605 A1	09-09-1992
		IE 990988 A1	13-12-2000
		IL 101110 A	08-12-1995
		IL 114570 A	31-10-1996
		JP 2955019 B2	04-10-1999
		JP 6504789 T	02-06-1994
		KR 235389 B1	15-12-1999
		NO 933069 A	01-11-1993
		NZ 241784 A	27-06-1995
		SG 46492 A1	20-02-1998
		SG 70625 A1	22-02-2000
		US 5977366 A	02-11-1999
		WO 9215582 A1	17-09-1992
		US 5605899 A	25-02-1997
		US 6348462 B1	19-02-2002
		US 5741909 A	21-04-1998
		US 5389640 A	14-02-1995
US 2002115861 A1	22-08-2002		
ZA 9201540 A	25-11-1992		

---